Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivaltinostat - CrystalGenomics

Next Previous
Drug Profile

Ivaltinostat - CrystalGenomics

Alternative Names: CG-200745; CG-745

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CrystalGenomics
  • Class Amides; Antineoplastics; Naphthalenes; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I/II Adenocarcinoma; Myelodysplastic syndromes; Pancreatic cancer

Most Recent Events

  • 23 Jan 2025 Efficacy data from phase I/II clinical trials in Adenocarcinoma released by CG Pharmaceuticals
  • 29 May 2024 Updated adverse events data from a phase I/II trial in Pancreatic cancer released by CG Pharmaceuticals
  • 18 Jan 2024 Efficacy data from a phase I/II trial in adenocarcinoma presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top